Clinical trials: Blood Disorder
Relapsed/Refractory Multiple Myeloma
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199…
- Trial name
- NCT01794520
- Testing
- Venetoclax, Dexamethasone
- Where
- 29 sites in United States, Belgium and 2 more
- Volunteers
- 117 people
- Sponsor
- AbbVie
Autism Spectrum Disorder, ASD
Cord Blood Infusion for Children With Autism Spectrum Disorder
This is a single site, prospective, randomized, double-blind study of a single intravenous autologous or allogeneic, unrelated cord blood (CB) infusion in children ages 2-7 years with Autism Spectrum Disorder (ASD).
- Conditions
- Autism Spectrum Disorder, ASD, Autism, PDD
- Trial name
- Duke ACT (NCT02847182)
- Testing
- Cord Blood Infusion
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Joanne Kurtzberg, MD
Hepatitis C
An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes
This is a prospective randomized controlled trial comparing two different clinic models for patients with hepatitis C. These patients commonly have mental health problems that are barriers to receiving HCV treatment.
- Trial name
- HCV (NCT00722423)
- Testing
- Integrated care model, Usual Care Model
- Where
- 3 sites in United States
- Volunteers
- 364 people
- Sponsor
- US Department of Veterans Affairs
Relapsed or Refractory Multiple Myeloma
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
The purpose of this Phase I study of vorinostat in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma is to determine the maximum tolerated dose (MTD) as estimated by the…
- Trial name
- NCT00642954
- Testing
- Vorinostat, Lenalidomide, Dexamethasone
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myelodysplastic Syndromes
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00045305
- Testing
- Cyclosporine, Methotrexate, Photopheresis
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Eastern Cooperative Oncology Group
GVHD, Adult Acute Myeloid Leukemia
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01295710
- Testing
- US-ATG-F
- Where
- 28 sites in United States, Australia
- Volunteers
- 260 people
- Sponsor
- Neovii Biotech
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.
- Trial name
- NCT00413413
- Testing
- Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg
- Where
- 19 sites in China
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Neutropenia, Breast Cancer
Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase I, dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of F-627 in female breast cancer patients who received up to 4 cycles of Epirubicin and Cyclophosphamide.
- Trial name
- NCT02527746
- Testing
- F-627, EC regimen
- Volunteers
- 18 people
- Sponsor
- EVIVE Biotechnology
Myelodysplastic Syndrome, Iron Overload
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
- Trial name
- NCT00110266
- Testing
- Deferasirox
- Where
- 48 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myelodysplastic Syndromes
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
RATIONALE: Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and HT before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00544466
- Testing
- fludarabine phosphate, melphalan, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- City of Hope Medical Center
Sickle Cell Disease
Imatinib for Pain in Sickle Cell Anemia
In this protocol, the investigators propose to evaluate the biochemical effects of imatinib on sickle red blood cells (RBCs). Patients will be administered imatinib mesylate orally following the guidelines previously established…
- Trial name
- IMPACT (NCT03997903)
- Testing
- Imatinib Mesylate
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV Infections
Rapid HIV Testing Program in the Emergency Department
The purpose of the study is to evaluate the feasibility of a rapid HIV testing program in the Temple University Hospital(TUH)Emergency Department.
- Trial name
- NCT00548041
- Testing
- HIV test by oral swab
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Temple University
HIV Infections
A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)
This study will investigate the safety and efficacy of MK-0518 versus efavirenz, in combination with TRUVADA, as a therapy for Human Immunodeficiency Virus (HIV)-infected patients not previously treated.
- Trial name
- NCT00369941
- Testing
- MK-0518, Comparator: efavirenz, Comparator: Truvada
- Volunteers
- 566 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myelogenous Leukemia
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
A phase II trial of CD3/CD19 depleted, IL-15 activated, donor natural killer (NK) cells in adults and subcutaneous IL-15 given after a preparative regimen for the treatment of relapsed or refractory acute myelogenous leukemia…
- Trial name
- NCT02395822
- Testing
- IL-15
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
This is a 4-stage, non-randomized, open-label, dose escalation and expansion, multicenter study. A cycle of therapy is 21 days. Stage 1 was a dose-escalation stage.
- Trial name
- NCT02113982
- Testing
- Tagraxofusp
- Where
- 9 sites in United States
- Volunteers
- 138 people
- Sponsor
- Stemline Therapeutics, Inc.
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Trial name
- NCT00275262
- Testing
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Sickle Cell Disease
Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
The objective of this study is to evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in patients with sickle cell disease.
- Trial name
- NCT01835496
- Testing
- single 1500 mg dose of Ferriprox
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- ApoPharma
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.
- Trial name
- CANDOR (NCT03158688)
- Testing
- Dexamethasone, Daratumumab, Carfilzomib
- Where
- 113 sites in United States, Australia and 17 more
- Volunteers
- 466 people
- Sponsor
- Amgen
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell…
- Trial name
- NCT03318861
- Testing
- KITE-585, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kite, A Gilead Company
Hepatitis B, Hepatitis A
Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 11, 12, 13, 14 and 15 after subjects received their first dose of a 3 dose primary vaccination schedule of combined hepatitis…
- Trial name
- NCT00289770
- Testing
- Twinrix™
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.